Suchergebnisse
Suchergebnisse:
Vor 13 Stunden · Covaxin is the first made-in-India Covid-19 vaccine, manufactured by Hyderabad-based Bharat Biotech, along with the ICMR. The study – by the lead authors Dr Upinder Kaur, assistant professor, department of pharmacology and Dr Sankha Shubhra Chakrabarti, head of department of geriatric medicine – thanks ICMR for “research support”.
Vor 14 Stunden · Covaxin and AstraZeneca’s COVID-19 vaccine, which was sold as Covishield in India, were the two main vaccines administered during India’s immunisation drive. Concerns about the safety of Covishield arose recently after AstraZeneca admitted its vaccine can cause a rare side effect of blood clotting. The British-Swedish pharma giant announced ...
Vor 15 Stunden · The study, titled "Long-Term Safety Analysis of the BBVl52 Coronavirus Vaccine in Adolescents and Adults: Findings from a 1-Year Prospective Study in North India" by Kaur et al., was published in the journal Drug Safety. India's banking sector hits historic high with over Rs 3 lakh crore net profit: PM Modi celebrates achievement
Vor 13 Stunden · New Delhi: India's main medical research organisation on Monday threatened legal action against Banaras Hindu University (BHU) while rejecting its findings that Bharat Biotech Ltd’s covid-19 ...
Vor 4 Stunden · Passengers arriving from Singapore will not be tested, nor will there be screening of passengers at the Chennai airport. Singapore is experiencing a new Covid-19 outbreak with newer variants.
Vor einem Tag · The study stated that nearly a third of 926 individuals who received the India-made Covaxin Covid-19 vaccine reported serious side-effects. ICMR Director General Dr Rajiv Bahl criticised the study for its poor methodology and design. The Indian Council of Medical Research (ICMR) has distanced itself from a follow-up study by two Benares Hindu ...
Vor 12 Stunden · A research paper, titled 'Long-Term Safety Analysis of the BBVl52 Coronavirus Vaccine in Adolescents and Adults: Findings from a l-Year Prospective Study in North India' stated that nearly one-third of the 926 participants in the study who received Bharat Biotech's anti-Covid vaccine Covaxin reported 'adverse events of special interest,' or AESI.
